Top Versus Top: Arcus Biosciences, Inc. (NYSE:RCUS), Abbott Laboratories (NYSE:ABT)

Arcus Biosciences, Inc. (NYSE:RCUS)

Arcus Biosciences, Inc. (NYSE:RCUS) closed at $7.11 on the last trading session with an increase of 1.57%, whereas, it previously closed at $7. The company has a market capitalization of $334.03 Million. The company traded shares of 70940 on the trading day while its three month average volume stands at 184.78 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Arcus Biosciences, Inc. (NYSE:RCUS) produced diluted EPS of -2.53. The EPS estimate for next year as estimated by analysts is at -2.28 while EPS for next quarter is estimated at -0.44. Earnings per Share growth for this year is reported at -12.4, while the analysts estimated the EPS growth for next year at -2.28% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 0%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Arcus Biosciences, Inc. (NYSE:RCUS) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Arcus Biosciences, Inc. (NYSE:RCUS) stands at 35.53 and Price to Book or P/B for the most recent quarter stands at 1.58. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Arcus Biosciences, Inc. (NYSE:RCUS) are reported at 8.6 and 8.6 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Arcus Biosciences, Inc. (NYSE:RCUS) stands at -26, -30.7 and -23.4 respectively

The trailing twelve month Revenue of Arcus Biosciences, Inc. (NYSE:RCUS) is reported at 9.4 Million with income of -68900000. The outstanding shares of Arcus Biosciences, Inc. (NYSE:RCUS) are 46.98 Million. The institutional Ownership of the shares of 46.3 stands at 0.80%, this figure is increased 0.16 in the last six months. The insider ownership for the shares of Arcus Biosciences, Inc. (NYSE:RCUS) is ticked at 1%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Arcus Biosciences, Inc. (NYSE:RCUS) is the Mean Target Price estimated by the analysts which stands at 19. The 52 week high of Arcus Biosciences, Inc. (NYSE:RCUS) is placed at 16.06 and 52 week low is standing at 6.30.

Performance wise the shares of Arcus Biosciences, Inc. (NYSE:RCUS) fell down -4.69% for the week, it also fell -15.86% for the monthly performance, while for the quarter it went up -28.4%. The shares decrease -33.86% for the half year and plummeted for the Year-To-Date performance. The shares of Arcus Biosciences, Inc. (NYSE:RCUS) shrinked -42.15% for the yearly performance.

Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) closed at $83.94 on the last trading session with an increase of 0%, whereas, it previously closed at $83.94. The company has a market capitalization of $148.48 Billion. The company traded shares of 4.95 Million on the trading day while its three month average volume stands at 5.13 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Abbott Laboratories (NYSE:ABT) produced diluted EPS of 1.64. The EPS estimate for next year as estimated by analysts is at 3.62 while EPS for next quarter is estimated at 0.84. Earnings per Share growth for this year is reported at 34.3, while the analysts estimated the EPS growth for next year at 3.62% and Earnings growth for next 5 years stands at 11.81% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 2%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Abbott Laboratories (NYSE:ABT) is at 51.06 while the forward p/e is at 23.19. The P/S or Price to Sales ratio of Abbott Laboratories (NYSE:ABT) stands at 4.8 and Price to Book or P/B for the most recent quarter stands at 4.69. The Price to Free Cash Flow ratio or P/FCF is reported at 75.22. The quick ratio and the current ratio of Abbott Laboratories (NYSE:ABT) are reported at 1.2 and 1.7 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Abbott Laboratories (NYSE:ABT) stands at 4.2, 9.4 and 6.1 respectively

The trailing twelve month Revenue of Abbott Laboratories (NYSE:ABT) is reported at 30.94 Billion with income of 2.92 Billion. The outstanding shares of Abbott Laboratories (NYSE:ABT) are 1.77 Billion. The institutional Ownership of the shares of 76 stands at 0.80%, this figure is increased 0.14 in the last six months. The insider ownership for the shares of Abbott Laboratories (NYSE:ABT) is ticked at 0.7%, the figure is plummeted -14.22% in the last six months.

Some other important financial aspects to be discussed here for Abbott Laboratories (NYSE:ABT) is the Mean Target Price estimated by the analysts which stands at 93.36. The 52 week high of Abbott Laboratories (NYSE:ABT) is placed at 88.76 and 52 week low is standing at 63.07.

Performance wise the shares of Abbott Laboratories (NYSE:ABT) fell down -1.89% for the week, it also fell -2.12% for the monthly performance, while for the quarter it went down 9.58%. The shares increase 13.48% for the half year and flew up for the Year-To-Date performance. The shares of Abbott Laboratories (NYSE:ABT) grew 31.92% for the yearly performance.

You may missed